Leukemia Posts - Page 2 of 69 on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva).  This study concluded that this treatment leads to an effective MRD reduction and has...

Read More

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML).  This study concluded that this treatment was safe and effective in the long-term in these...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new targeted therapy drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.  Some background Treatments for...

Read More

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Posted by on Nov 14, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of fixed-duration treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that fixed-duration treatment with ibrutinib plus venetoclax was...

Read More

Evaluating the cardiovascular side effects in patients with chronic lymphocytic leukemia who received acalabrutinib.

Evaluating the cardiovascular side effects in patients with chronic lymphocytic leukemia who received acalabrutinib.

Posted by on Nov 7, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the cardiovascular (CV; heart and blood vessels) side effects in patients with chronic lymphocytic leukemia (CLL) who received acalabrutinib (Calquence) treatment. The data showed that the occurrence of CV side effects with acalabrutinib treatment is very low in patients with CLL. Some background CLL is a type of...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Fertility preservation for young people with blood cancer

Fertility preservation for young people with blood cancer

Posted by on Oct 31, 2021 in Leukemia | 0 comments

In a nutshell This review looked at options to preserve future fertility for young people diagnosed with blood cancer.  Some background For teens and young adults, blood and bone marrow cancers are one of the most common types of cancer. These include Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and acute leukemia. Fortunately, blood...

Read More

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

Posted by on Oct 17, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the treatment effects of all-trans retinoic acid (ATRA; Vesanoid) and arsenic trioxide (ATO; Trisenox), compared to ATRA with standard chemotherapy on long-term health-related quality of life (HRQoL) in patients with acute promyelocytic leukemia (APL). The data showed better long-term HRQoL measures in patients treated...

Read More

Evaluating minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia 

Evaluating minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia 

Posted by on Oct 16, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to investigate the prognostic value of minimal residual disease (MRD) in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).  This review concluded that MRD is a good predictor of outcomes in these patients.   Some background Ph+ ALL is an aggressive type of...

Read More